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A B S T R A C T
Aspirin, one of the most widely used non-steroidal anti-inflammatory drugs, has extensively studied effects on
the cardiovascular system. To reveal further pleiotropic, beneficial effects of aspirin on a number of pro- and
anti-inflammatory microglial mechanisms, we performed morphometric and functional studies relating to phago-
cytosis, pro- and anti-inflammatory cytokine production (IL-1β, tumor necrosis factor-α (TNF-α) and IL-10, re-
spectively) and analyzed the expression of a number of inflammation-related genes, including those related to
the above functions, in pure microglial cells. We examined the effects of aspirin (0.1 mM and 1 mM) in un-
challenged (control) and bacterial lipopolysaccharide (LPS)-challenged secondary microglial cultures. Aspirin af-
fected microglial morphology and functions in a dose-dependent manner as it inhibited LPS-elicited microglial
activation by promoting ramification and the inhibition of phagocytosis in both concentrations. Remarkably, as-
pirin strongly reduced the pro-inflammatory IL-1β and TNF-α production, while it increased the anti-inflamma-
tory IL-10 level in LPS-challenged cells. Moreover, aspirin differentially regulated the expression of a number of
inflammation-related genes as it downregulated such pro-inflammatory genes as Nos2, Kng1, IL1β, Ptgs2 or Ccr1,
while it upregulated some anti-inflammatory genes such as IL10, Csf2, Cxcl1, Ccl5 or Tgfb1. Thus, the use of as-
pirin could be beneficial for the prophylaxis of certain neurodegenerative disorders as it effectively ameliorates
inflammation in the brain.
1. Introduction
Microglia is the principal immune cell in the central nervous sys-
tem (CNS). Under pathophysiological conditions such as injury, in-
fection or neurodegeneration (Kettenmann et al., 2011; Kreutzberg,
1996) microglia become activated that proliferate, phagocytose and
release pro- and anti-inflammatory cytokines, growth factors or reac-
tive species (Gehrmann et al., 1995; Hanisch, 2002; Kreutzberg, 1996;
Luo and Chen, 2012; Smith et al., 2012). Neuroinflammatory
processes are strongly associated with the development of Alzheimer’s
disease (AD; Akiyama et al., 2000; McGeer and McGeer, 2004), Parkin-
son’s disease (PD; Phani et al., 2012; Shin et al., 2015) and multi-
ple sclerosis (MS; Minagar et al., 2002; Muzio et al., 2007). In AD,
for example, β-amyloid accumulation leads to the production of cy-
tokines (IL-1β, IL-6, TNF-α) and the activation of nitric oxide synthase
(Nos) gene through the nuclear transcription factor kappa B (NF-κB)
signaling pathway (Medeiros et al., 2007). IL-1β in turn increases the
expression of amyloid precursor protein (Ge and Lahiri, 2002), while
increased expression of TNF-α is reported for both MS
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and PD (Minagar et al., 2002). Strong anti-inflammatory mechanisms
can also lead to the development of neurodegenerative diseases
(Gehrmann et al., 1995; Ghosh et al., 2013; Gonzalez-Scarano and
Baltuch, 1999; Graeber, 2010; Streit, 2002).
Aspirin (acetylsalicylic acid) is one of the most commonly used
non-steroidal anti-inflammatory drugs (NSAIDs). By inhibiting the en-
zyme cyclooxygenase (COX; prostaglandin-endoperoxide synthase, EC
1.14.99.1) it blocks the conversion of arachidonic acid to prostanoids
(Vane and Botting, 2003). Apart from its well known beneficial anti-in-
flammatory effects in the cardiovascular system (Amann and Peskar,
2002) and its role in anti-cancer therapy (Cuzick et al., 2014), it also has
widespread effects on immune cell functions such as NO production, cy-
tokine (e.g. IL-1β, IL-6, IL-8, TNF-α) and adhesion molecule expression
(Hussain et al., 2012). Its anti-inflammatory function is based on the
inhibition of the NF-κB signaling pathway (Amann and Peskar, 2002),
while its neuroprotective effect in the injured brain is linked to COX-2
inhibition; overexpression of COX-2 is indicative of neuronal damage
(Berk et al., 2013; Strauss, 2008). Although aspirin has not been exten-
sively studied in microglia, its anti-inflammatory actions are recently re-
ported (Medeiros et al., 2013; Wang et al., 2011; Yang et al., 2014).
In the present study we investigated the pleiotropic effects of aspirin
on secondary, pure microglial cultures derived from mixed primary cul-
tures of 18-day-old embryonic (E18) rat forebrains under control (un-
challenged) and bacterial lipopolysaccharide (LPS)-challenged condi-
tions (Gresa-Arribas et al., 2012; Kata et al., 2016; Lund et al., 2006). To
reveal the effects of aspirin on pro- and anti-inflammatory mechanisms,
we performed quantitative morphometric, functional and gene expres-
sion studies relating to phagocytic capability, pro- and anti-inflamma-
tory cytokine production (IL-1β, TNF-α, and IL-10, respectively) and the
expression of various genes related to inflammation. A preliminary re-
port on the effects of aspirin on pure microglial cultures was presented
in poster form (Kata and Gulya, 2014).
2. Material and methods
2.1. Animals
All animal experiments were carried out in strict compliance with
the European Council Directive (86/609/EEC) and EC regulations (O.J.
of EC No. L 358/1, 18/12/1986) regarding the care and use of lab-
oratory animals for experimental procedures, and followed the rele-
vant Hungarian and local legislation requirements. The experimental
protocols were approved by the Institutional Animal Welfare Com-
mittee of the University of Szeged (I-74-II/2009/MÁB). The pregnant
Sprague-Dawley rats (170–190 g) were kept under standard housing
conditions and fed ad libitum.
2.2. Antibodies
For a thorough characterization of different microglial phenotypes
developed in vitro, an antibody against the ionized calcium binding
adaptor molecule 1 (Iba1), an intracellular actin- and Ca⁠2+-binding pro-
tein expressed in the CNS specifically in macrophages and microglia
(Ahmed et al., 2007), was used in our immunocytochemical and West-
ern blot analyses. The anti-glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) antibody was used as an internal control in Western blot ex-
periments (Wu et al., 2012). Antibody dilutions, incubation times and
blocking conditions were tested for both immunocytochemistry and
Western blot analysis. To detect the specificities of the secondary an-
tisera, staining without the primary antibody was performed. In such
cases, no fluorescent or Western blot signals were detected.
2.3. Cell cultures
Pure microglial cells were isolated from mixed primary cortical cell
cultures of rat embryos of either sex by the method we described ear-
lier (Kata et al., 2016; Szabo and Gulya, 2013). Sibling embryos ob-
tained from the same pregnancy were processed for culturing together;
each pregnancy was considered as an independent experiment. Briefly,
10–12 fetal rats (E18) under anesthesia were decapitated and the frontal
lobe of the cerebral cortex was removed, minced with scissors, incu-
bated in 9 ml Dulbecco’s Modified Eagle’s Medium (DMEM; Invitro-
gen, Carlsbad, USA) containing 1 g/l D-glucose, 110 mg/l Na-pyruvate,
4 mM L-glutamine, 3.7 g/l NaHCO⁠3, 10,000 U/ml penicillin G, 10 mg/
ml streptomycin sulfate, 25 μg/ml amphotericin B and 0.25% trypsin
for 10 min at 37 °C, and then centrifuged at 1000 g for 10 min at room
temperature (RT). The pellet was resuspended, washed twice in 5 ml
DMEM containing 10% heat-inactivated fetal bovine serum (FBS; Invit-
rogen) and centrifuged for 10 min at 1000 g at RT. The final pellet was
resuspended in 2 ml DMEM/10% FBS, after which the cells were plated
in the same medium on a poly-l-lysine-coated culture flask (75 cm⁠2,
12 × 10⁠6 cell/flask) and cultured for a number of days in vitro (DIV)
at 37 °C in a humidified air atmosphere supplemented with 5% CO⁠2, in
one or other of the following ways: 1) in poly-l-lysine-coated coverslips
(15 × 15 mm; 2 × 10⁠5cells/coverslip) for immunocytochemistry; 2) in
poly-l-lysine-coated Petri dishes (60 mm x 15 mm; 4 × 10⁠5 cells/dish)
for Western blot and enzyme-linked immunosorbent assays (ELISA); or
3) in a poly-l-lysine-coated culture flask (75 cm⁠2, 12 × 10⁠6 cells/flask)
for the subsequent generation of pure microglial cell cultures.
Secondary microglial cells were subcloned from mixed primary cul-
tures (DIV7) maintained in a poly-l-lysine-coated culture flask (75 cm⁠2,
12 × 10⁠6 cells/flask) by shaking the cultures at 100 rpm in a platform
shaker for 30 min at 37 °C. Microglia from the supernatant were col-
lected by centrifugation at 3000 g for 8 min at RT and resuspended in
2 ml DMEM/10% FBS. The cells were seeded at a density of 4 × 10⁠5
cells/Petri dish for Western blots or 2 × 10⁠5 cells/coverslip/Petri dish
for immunocytochemistry or phagocytosis assays, and cultured in
DMEM in a humidified atmosphere supplemented with 5% CO⁠2 at 37 °C.
The medium was changed on the first day after seeding (subDIV1).
2.4. Cell culture treatments
The aspirin concentrations used in our study are comparable to the
therapeutic plasma salicylate levels for pain relief, inhibition of platelet
aggregation or anti-inflammation (Higgs et al., 1987). On the fourth day
of subcloning (subDIV4), DMEM was replaced and the expanded pure
microglial cells were treated with either bacterial lipopolysaccharide
(LPS; 20 ng/ml final conc., dissolved in DMEM; Sigma, St. Louis, MO,
USA) or aspirin (0.1 mM (low) and 1 mM (high) final conc., from ≥99%
acetylsalicylic acid dissolved in sterile, distilled water; Sigma) alone, or
with a combination of LPS + aspirin, and the effects were compared in
a variety of morphological and functional tests. LPS treatment served
as an immunochallenge. Six types of treatment regimens were used:
1) control (unchallenged and untreated) cultures; 2) LPS-challenged
cultures received 20 ng/ml LPS; 3) aspirin-treated cultures received
0.1 mM aspirin; 4) aspirin-treated cultures received 1 mM aspirin; 5)
LPS-challenged + aspirin-treated cultures were challenged with 20 ng/
ml LPS and treated with 0.1 mM aspirin; 6) LPS-challenged + as-
pirin-treated cultures were challenged with 20 ng/ml LPS and received
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1 mM aspirin. Depending on the experiments, the treatments lasted for
6 or 24 h at 37 °C.
2.5. Immunocytochemistry
Pure secondary microglial cultures treated with different treatment
regimens were fixed on coverslips with 4% formaldehyde for 5 min and
rinsed with 0.05 M phosphate-buffered saline (PBS) for 2 × 5 min. After
permeabilization and blocking of the nonspecific sites in 0.05 M PBS so-
lution containing 5% normal goat serum (Sigma), 1% heat-inactivated
bovine serum albumin (Sigma) and 0.05% Triton X-100 for 30 min at
37 °C, the cells on the coverslips were incubated overnight in a humid-
ified chamber at 4 °C with rabbit anti-Iba1 polyclonal antibody (1:500
final dilution; Wako, Japan) in the above solution (Kata et al., 2016).
The cultured cells were washed for 4 × 10 min at RT in 0.05 M PBS,
and then incubated with the Alexa Fluor 568 fluorochrome-conjugated
goat anti-rabbit antibody (1:1000 final dilution; Invitrogen) in the dark
for 3 h at RT. The cells on the coverslip were washed for 4 × 10 min in
0.05 M PBS at RT, and the nuclei were stained in 0.05 M PBS solution
containing 1 mg/ml polyvinylpyrrolidone and 0.5 μl/ml Hoechst 33258
dye (Sigma). The coverslips were rinsed in distilled water for 5 min,
air-dried and mounted on microscope slides in Vectashield mounting
medium (Vector Laboratories, Burlingame, CA, USA).
2.6. Western blot analysis
Cultured microglial cells (subDIV4) were collected through use of a
rubber policeman, homogenized in 50 mM Tris-HCl (pH 7.5) contain-
ing 150 mM NaCl, 0.1% Nonidet P40, 0.1% cholic acid, 2 μg/ml le-
upeptin, 1 μg/ml pepstatin, 2 mM phenylmethylsulfonyl fluoride and
2 mM EDTA, and centrifuged at 10,000g for 10 min (Kata et al., 2016;
Szabo and Gulya, 2013). The pellet was discarded and the protein con-
centration of the supernatant was determined (Lowry et al., 1951).
For the Western blot analyses, 5–10 μg of protein was separated on
a sodium dodecyl sulfate/polyacrylamide gel (4%/10% stacking gel/
resolving gel), transferred onto Hybond-ECL nitrocellulose membrane
(Amersham Biosciences, Little Chalfont, Buckinghamshire, England),
blocked for 1 h in 5% nonfat dry milk in Tris-buffered saline (TBS)
containing 0.1% Tween 20, and incubated overnight with either a rab-
bit anti-Iba1 polyclonal antibody (1:1000 final dilution; Wako) or a
mouse anti-GAPDH monoclonal antibody (clone GAPDH-71.1; 1:20,000
final dilution; Sigma). The membranes were rinsed 5 times in 0.1%
TBS-Tween 20 and incubated for 1 h with the peroxidase-conjugated
goat anti-rabbit secondary antibody (1:2000 final dilution; Invitrogen)
for Iba1 or with the peroxidase-conjugated rabbit anti-mouse secondary
antibody (1:2000 final dilution; Sigma) for GAPDH Western blots, then
washed 5 times as before. The enhanced chemiluminescence method
(ECL Plus Western blotting detection reagents; Amersham Biosciences)
was used to reveal immunoreactive bands according to the manufac-
turer’s protocol.
2.7. In vitro phagocytosis
The fluid-phase phagocytic capabilities of the control and variously
treated pure microglial cell cultures were determined via the uptake of
fluorescent microspheres (carboxylate-modified polystyrene beads, flu-
orescent yellow-green (λex ∼ 470 nm; λem ∼ 505 nm), aqueous suspen-
sion, 2.0 μm mean particle size; L4530, Sigma) as we described pre-
viously (Szabo and Gulya, 2013; Szabo et al., 2016). Unchallenged
(control) and LPS-challenged pure microglial cell cultures (subDIV4)
with or without aspirin treatments
were tested for 24 h. At the end of the treatment period, 1 μl of a 2.5%
aqueous suspension of fluorescent microspheres per ml was added to
the culture, which was then incubated for 60 min at 37 °C. The cells
were next washed 5 times with 2 ml of PBS to remove dish- or cell
surface-bound residual fluorescent microspheres, and fixed with 4%
formaldehyde in PBS. In another setup, we also determined the num-
ber of cell membrane-associated but not phagocytosed beads. Such neg-
ative controls were treated as above with the exception that microglial
cultures with beads were incubated for 60 min at 4 °C. At this tem-
perature, the number of beads associated with cell surface averaged
less than 1 bead/100 Iba1-labeled cells, thus the phagocytosis was not
considered significant. For measurement of the phagocytotic activity,
cells labelled with phagocytosed microbeads and processed for Iba1 im-
munocytochemistry were counted in 20 random fields in each treatment
group (mean ± SEM) under a 20× or 40× objective. Statistically signifi-
cant differences were determined by two-way ANOVA.
2.8. Determination of IL-1β, IL-10 and TNF-α
Our protocols for ELISA assays were described previously (Kata et
al., 2016). Briefly, the supernatants were collected from each treat-
ment and stored at −20 °C. Concentrations of IL-1β, IL-10 and TNF-α
were measured with rat-specific ELISA kits (eBioscience, Vienna, Aus-
tria). The sensitivity of IL-1β (Cat# BMS630), IL-10 (Cat# BMS629) and
TNF-α (Cat#BMS622) assays was 4 pg/ml, 1.5 pg/ml and 11 pg/ml, re-
spectively. As stated by the manufacturer, the overall intra- and interas-
say coefficients of variation were <10% in both cases for IL-1β and
TNF-α, and <5% in both cases for IL-10.
2.9. RNA isolation
Total RNA from control and treated pure microglial cells was puri-
fied as described previously (Fabian et al., 2011); columns and wash
buffer were from Bioneer (Viral RNA extraction kit; Daejon, South Ko-
rea). Briefly, cells were washed with PBS, incubated in lysis buffer (RA1;
Macherey-Nagel, Düren, Germany), then collected and mixed with 70%
ethanol in RNase-free water (Bioneer). The mixture was transferred
through columns (Bioneer) and washed with 350 μl 80% ethanol in di-
ethylpyrocarbonate-treated water, and then with 600 μl and 300 μl W2
wash buffer (Bioneer). Total RNA was eluted in 50 μl RNase free-wa-
ter. One μl RNase inhibitor (Applied Biosystems, Foster City, CA, USA)
was added to the samples. The quality and quantity of the isolated RNA
was measured with NanoDrop1000 Version 3.8.1. (Thermo Scientific,
Budapest, Hungary).
2.10. RNA expression
Reverse transcription from 3 μg total RNA in 30 μl was performed
with the High Capacity cDNA Archive Kit (Applied Biosystems) accord-
ing to the manufacturer’s protocol as described previously (Kata et al.,
2016). cDNA was diluted to 80 μl with nuclease-free water. The instru-
mentation included the Bravo automatic liquid handling system (Agi-
lent Technologies, Inc., Santa Clara, CA, USA) for polymerase chain re-
action (PCR) assay preparation and a LightCycler 1536 System (Roche
Diagnostics Corp., Indianapolis, IN, USA) or a Light Cycler Nano In-
strument (Roche) for cycling (Woudstra et al., 2013). The expression of
116 inflammation-related genes, together with that of 6 control genes
(see below), was measured with Universal Probe Library assays using
intron-spanning gene-specific primers (Rat Immune Panel; Avidin Ltd.,
Szeged, Hungary, www.avidinbiotech.com/custom-pathways/) and the
LightCycler 1536 DNA Probe Master kit (Roche). Moreover, the ex-
pression of certain
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phagocytosis-related genes such as the integrin associated protein or
cluster of differentiation 47 (Cd47, NM_019195_2), the engulfment or
cell motility protein (Elmo1, NM_001108415.1), the scavenger recep-
tor class B member 1 (Scarb1, NM_031541_1), the plasminogen activa-
tor inhibitor-1 (Serpine1, NM_012620_1), the signal-regulatory protein
α (Sirpa, NM_013016_2) and the vesicle-associated membrane protein 7
(Vamp7, NM_053531_1) were also analyzed by the Light Cycler Nano In-
strument. For the 1536 System, each 2 μl PCR reaction contained 8 ng
cDNA, 0.4 μl LightCycler DNA Probes Master (5x), the corresponding
primer set and UPL probe and the Setup Control (Kata et al., 2016).
The PCR cycling protocol was as follows: enzyme activation at 95 °C for
60 s, 50 cycles of denaturation at 95 °C for 0 s, and annealing and ex-
tension at 60 °C for 30 s. For the Nano Instrument, each 20 μl PCR reac-
tion contained 20 ng cDNA, 10 μl Lightcycler DNA Probes Master (5x),
the corresponding primer set and UPL probe and the Setup Control. The
PCR protocol was as follows: enzyme activation at 95 °C for 10 min, 50
cycles of denaturation at 95 °C for 15 s, and annealing and extension at
60 °C for 30 s. Gene expression was normalized to the average values
of clathrin, heavy chain (Cltc, NM_019299.1), Gapdh (M17701.1), glu-
curonidase, beta (Gusb, NM_017015.2), hypoxanthine phosphoribosyl-
transferase 1 (Hprt1, NM_012583.2), phosphoglycerate kinase 1(Pgk1,
NM_053291.3), and tubulin, beta 5 class I (Tubb5, NM_173102.2) ex-
pression as endogenous controls and expressed relative to the unchal-
lenged controls by using the 2⁠−ΔΔCt method.
A total of 122 gene-specific assays were run on 3 independent sam-
ples from each condition. Student’s t-test and two-way ANOVA were ap-
plied for the analysis of significance where p < 0.05 was considered sig-
nificant. Gene expression was analyzed by GraphPad Prism 6 (GraphPad
Software, Inc., La Jolla, CA, USA). For hierarchical cluster analysis and
visualization, the Hierarchical Clustering Explorer (v3.0) software was
used (Human-Computer Interaction Lab., University of Maryland, MD,
USA; publicly available at http://www.cs.umd.edu/hcil/multi-cluster/
hce3.html). The complete linkage clustering method was applied with
Euclidean distance metric.
2.11. Image analysis and statistics
Digital images were captured by a Nikon Microphot-FXA epifluores-
cent microscope (Nikon Corp., Tokyo, Japan), using a Spot RT Color
CCD camera and the Spot RT software (Spot RT/ke Diagnostic In-
struments, Sterling Heights, MI, USA). For the determination of mi-
croglial cell purity, Hoechst 33258-labelled cell nuclei that belonged
to Iba1-immunopositive cells were counted on coverslip-cultured sam-
ples. For each culture, 50–100 randomly selected microscope fields
were analyzed. In every case, the cultures had, on average, at least
99 Iba1-positive somata for 100 Hoechst 33258-labelled cell nuclei
(>99% purity for microglial cells). Phagocytosed microspheres on 20
randomly sampled microscope fields from 3 coverslips for each treat-
ment regimen were counted with the use of the computer program
ImageJ (version 1.47; http://rsb.info.nih.gov/ij). For the measurement
of area (μm⁠2), perimeter (μm) and transformation index (TI), Iba1-im-
munoreactive microglial cell images were converted into binary replicas
by using thresholding procedures implemented by ImageJ and Adobe
Photoshop CS5.1 software (Adobe Systems, Inc., San Jose, CA, USA)
as we published earlier (Kata et al., 2016; Szabo and Gulya, 2013;
Szabó et al., 2016). TI was determined (Fujita et al., 1996) accord-
ing to the following formula: [perimeter of cell (μm)]⁠2/4π [cell area
(μm⁠2)]. Color correction and cropping of the light microscopic im-
ages were performed when photomicrographs were made for publi-
cation and assembled for a panel. Gray-scale digital images of the
immunoblots were acquired by scanning the autoradiographic films
with a desktop scanner and processed at identi
cal settings to allow comparisons of the Western blots from different
samples. The bands were analyzed through the use of ImageJ. The im-
munoreactive densities of equally loaded lanes were quantified, and all
samples were normalized to the internal GAPDH load controls.
All statistical comparisons were made by using R 3.1.0 for Win-
dows (The R Foundation for Statistical Computing; Vienna University of
Economics and Business, Vienna, Austria). Results were analyzed with
two-way ANOVA, and the Bonferroni correction was used to establish
significance between groups. Values were presented as means ± SEM;
p < 0.05 was considered significant; *, ** and *** denote p < 0.05,
p < 0.01 and p < 0.001, respectively.
3. Results
3.1. Aspirin regulates microglial morphology in vitro
Microglial morphology was analyzed on pure microglial cultures
4 days after seeding (subDIV4). Immunocytochemistry routinely per-
formed on these secondary cultures consistently detected a >99% in-
cidence of the Iba1 immunopositive microglial cells for the Hoechst
33258 dye-labeled cell nuclei (Fig. 1). The morphological changes
elicited by aspirin treatments in unchallenged and LPS-challenged pure
microglia cultures (Fig. 2A–F) were quantitatively analyzed on binary
silhouettes of individual microglial cells (Fig. 3A–I). Iba1 protein ex-
pression was also monitored during treatments (Fig. 2G). The amount of
Iba1 immunoreactivity was significantly increased in the aspirin-treated
(low: 2.09 ± 0.17; high: 2.22 ± 0.26) and the LPS-challenged + as-
pirin-treated groups (low: 2.30 ± 0.29; high: 2.49 ± 0.32) as compared
to LPS-challenged values (1.35 ± 0.14; Fig. 2G). Most of the unchal-
lenged and untreated (control) microglia displayed slightly amoeboid/
ramified morphology with TI = 6.44 ± 1.33; they typically had only a
few short processes (Figs. 2A, 3A). LPS challenge resulted in a signifi-
cant change in morphology (Figs. 2B, 3B, G–I) as amoeboid morpholo-
gies with low TI values (1.37 ± 0.03) were more typical; LPS challenge
decreased area, perimeter and TI values (by 48%, 65% and 78%, re-
spectively) as compared to the controls. When LPS-challenged cells were
treated with aspirin, significantly enlarged and more ramified cells were
seen as compared to the values of the LPS-challenged cells (Figs. 2B,
E, F, 3B, E–I) indicating that aspirin was able to reverse the morpho
Fig. 1. Localization of Iba1 immunoreactive microglial cells in a pure secondary mi-
croglial culture (subDIV4).The typical purity of the culture is >99%; in this representative
photomicrograph of a field of view the purity is 100% since every Hoechst 33258-labeled
cell nuclei (blue) is surrounded by Iba1 immunopositive cytoplasm (red). Scale bar: 50 μm.
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Fig. 2. Aspirin affects microglial morphology and Iba1 immunoreactivity in pure microglial cells.Pure microglia cell cultures (subDIV4) were maintained as described in the Methods
section. (A–F) Representative fluorescent immunocytochemical pictures demonstrate the typical cellular distribution of Iba1 immunoreactivity (red) in A) control (unchallenged and
untreated), B) LPS-challenged, C) 0.1 mM aspirin treated, D) 1 mM aspirin treated, E) LPS-challenged + 0.1 mM aspirin-treated and F) LPS-challenged + 1 mM aspirin-treated microglial
cells. Hoechst 33258-labeled cell nuclei are shown in blue. Scale bar in A (for all pictures): 50 μm. G, Quantitative Western blot analysis of Iba1 and GAPDH immunoreactivities in pure
microglial cell cultures. Protein samples from the cultures were separated by gel electrophoresis, transferred to nitrocellulose membranes and probed with either the Iba1 or the GAPDH
antibody. Gray scale digital images of the immunoblots were acquired by scanning the autoradiographic films with a desktop scanner. The images were scanned and processed at identical
settings to allow comparisons between the Western blots from different samples. Error bars indicate integrated optical density values (means ± SEM) normalized to the internal standard
GAPDH. Representative Western blot pictures are shown beside the graph. Data were analyzed with two-way analysis of variance (ANOVA). *p < 0.05, **p < 0.01.
logical changes induced by LPS-challenge. Both aspirin doses increased
the TI values to the control level (low: 5.73 ± 0.56; high: 7.36 ± 0.61)
and induced ramified morphology with thick processes and microspikes
(Figs. 2E, F; 3E, F).
3.2. Aspirin inhibits increases in LPS-induced phagocytosis by microglia
Unchallenged and untreated microglia exhibited a low level of
fluid-phase phagocytosis engulfing only 3.63 ± 0.21 beads per cell
(n = 60; Fig. 4A, G). As expected, microglial activation was associ-
ated with robust phagocytic activity as LPS challenge increased phago-
cytosis significantly to about 350% of the control level (12.87 ± 0.65;
n = 58; Fig. 4A, B, G). Aspirin alone did not affect the phagocyto-
sis appreciably (Fig. 4C, D, G), as the number of
phagocytosed microbeads remained low in both cases (low: 2.72 ± 1.19,
high: 3.30 ± 0.22; n = 60). However, aspirin inhibited phagocytosis
significantly in LPS-challenged microglia (Fig. 4E, F, G). Aspirin
(0.1 mM or 1 mM) decreased phagocytosis dose-dependently by about
30% (9.20 ± 0.59; n = 55; Fig. 4E, G) and 70% (3.86 ± 0.23 mi-
crobeads per cell; n = 67; Fig. 4F, G), respectively, as compared to LPS
treatment.
3.3. Aspirin strongly influences both pro- and anti-inflammatory cytokine
levels
Activated microglia express several inflammatory cytokines. When
the basal levels of the pro-inflammatory cytokines IL-1β and TNF-α
and the anti-inflammatory cytokine IL-10 in unchallenged mi
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Fig. 3. Quantitative analysis of microglial morphology in pure microglial cell cultures after different treatments.Pure microglial cell cultures (subDIV4) were maintained as described in the
Methods section. (A–F) Iba1-positive microglial cells from pure microglial cultures (subDIV4) were photographed, the pictures were digitized and the morphological characteristics were
quantitatively analyzed on binary silhouettes of unchallenged (A), LPS-challenged (B), 0.1 mM aspirin treated (C), 1 mM aspirin treated (D), LPS-challenged + 0.1 mM aspirin-treated
(E) and LPS-challenged + 1 mM aspirin-treated (F) microglia. Four representative binary silhouettes are shown for each culturing protocol. Scale bar for all silhouettes: 50 μm.
Area (G) in μm⁠2, perimeter (H) in μm, and TI values (I), calculated as [perimeter of cell (μm)]⁠2/4π[cell area (μm⁠2)], are
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indicated for each digitized cell. Unchallenged and untreated (control) microglia displayed slightly amoeboid/ramified morphology, and neither of the aspirin treatments changed the
control values significantly. LPS challenge resulted in amoeboid morphology with the accompanying significant morphometric changes. Both aspirin treatments in LPS-challenged cells
resulted in an enlarged and more ramified cell form with a much larger area, perimeter, and TI value as compared with the LPS results (B, E, F, G, H, I). In the control and the aspirin
treated cultures, cells displayed short processes or small pseudopodia with a concurrent slight ramification (A, C, D). In the LPS-challenged cultures (B), the microglia became smaller and
showed amoeboid morphology. Aspirin treatments in these cells (E, F) resulted in a much larger area (G) but similar perimeter (H) and TI values (I) as compared the control cultures.
(G) Average area (in μm⁠2 ± SD) measurements for cultured pure microglial cells. (H) Average perimeter (in μm ± SEM) measurements for cultured pure microglial cells. (I) Average TI
values (±SEM) for cultured pure microglial cells. For (G–I), error bars indicate means ± SEM of 6 replicate measurements from 3 independent culturing. Data were analyzed with two-way
analysis of variance (ANOVA). *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 4. Aspirin strongly inhibits phagocytosis.Pure microglial cultures (subDIV4) were maintained and treated with fluorescent microbeads (2 μm in diameter) as described in the Methods
section. Iba1-specific fluorescent immunocytochemistry (red: microglia; blue: nucleus; green: microspheres) on unchallenged (A), LPS-challenged (B), 0.1 mM aspirin treated (C), 1 mM
aspirin treated (D), LPS-challenged + 0.1 mM aspirin-treated (E), and LPS-challenged + 1 mM aspirin-treated (F) microglia. Scale bar in A (for all pictures) = 50 μm. (G) Quantitative
analysis of the number of phagocytosed microbeads revealed that LPS dramatically activated phagocytosis, while aspirin significantly decreased this microglial function. Error bars indicate
means ± SEM of 6 replicate measurements from 3 independent culturing. Data were analyzed with two-way ANOVA. *p < 0.05, ***p < 0.001.
croglia were compared with the levels from aspirin-treated LPS-chal-
lenged cells, a unique regulatory pattern emerged (Fig. 5). In the case
of IL-1β the basal level in unchallenged (control) microglia was
22.45 ± 2.87 pg/ml (Fig. 5A). Both aspirin treatments were able to
change this level (low: 10.26 ± 2.62 pg/ml; high: 10.19 ± 2.23 pg/ml).
As expected, LPS challenge significantly elevated the IL-1β level to
336.15 ± 51.72 pg/ml. However, co-incubation of LPS and 1 mM as-
pirin significantly inhibited IL-1β level by about 50%, to
169.6 ± 19.42 pg/ml, while 0.1 mM aspirin decreased it by about
16.5%, to 280.05 ± 25.0 pg/ml (Fig. 5A).
A similarly strong effect of aspirin was demonstrated on the level
of TNF-α, another pro-inflammatory cytokine, in LPS-challenged mi-
croglial cells (Fig. 5C, D). Two different treatment periods (6 h and
24 h) were used as the TNF-α production responded quickly to the
LPS challenge. The level of TNF-α in the control group could not be de-
tected, but its level quickly rose, to 1187 ± 94.12 pg/ml in the LPS-chal-
lenged cells after 6 h, and the level was still elevated after 24 h
(189.92 ± 27.4 pg/ml). Aspirin treatments (0.1 mM and 1 mM) resulted
in small, detectable TNF-α levels for both doses (27.69 ± 2.89 pg/ml
and 29.23 ± 1.73 pg/ml after 6 h, while 8.24 ± 1.81 pg/ml and
9.09 ± 0.6 pg/ml after 24 h). When aspirin was co-administered to
LPS-challenged cells for either 6 h or 24 h, it inhibited the production of
TNF-α in both cases, but only the high aspirin concentration decreased
the TNF-α level significantly by about 25% (to 844.76 ± 67.11 pg/ml
after 6 h) and 50% (96.79 ± 6.02 pg/ml after 24 h) (Fig. 5C, D).
Aspirin also affected the production of IL-10 (Fig. 5B). LPS chal-
lenge increased the basal IL-10 level (24.98 ± 3.47 pg/ml) signifi
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Fig. 5. Aspirin reduces the pro-inflammatory cytokine IL-1β and TNF-α levels and increases the anti-inflammatory IL-10 production.Pure microglial cultures (subDIV4) were maintained
and treated as described in the Methods section. After treatments for 6 or 24 h, immunoreactive protein levels (pg/ml ± SD) for IL-1β (A), TNF-α (C, D) and IL-10 (B) were detected by
ELISA. TNF-α production was measured after 6 h and 24 h (C, D). As expected, pro-inflammatory cytokine production was significantly increased in the LPS-challenged cells (A, C, D).
Aspirin (1 mM) inhibited this effect for both IL-1β (A) and TNF-α (C, D). The level of the anti-inflammatory cytokine IL-10 was measured after 24 h (B). Aspirin (0.1 mM and 1 mM) did
not increase the level of IL-10 in unchallenged cultures but strongly increased it in LPS-challenged cultures (to 115% and 130% of the control values, respectively) (B). Error bars indicate
means ± SEM of 6 replicate measurements from 3 independent culturing. Data were analyzed with two-way ANOVA. n.d. = not detected. *p < 0.05; **p < 0.01, ***p < 0.001.
cantly (134.0 ± 9.9 pg/ml). When aspirin was co-administered with
LPS, the IL-10 protein expression was further increased as compared
to the LPS challenged value (low: 309.47 ± 12.29 pg/ml, high:
280.95 ± 30.3 pg/ml). Aspirin administered alone to unchallenged cells
had no significant effects on the microglial IL-10 levels.
3.4. Aspirin affects the expression of inflammation-related genes
We analyzed the effects of aspirin on the expression of 116 in-
flammation-related genes in unchallenged and LPS-challenged pure mi-
croglial cells with or without aspirin treatment. The hierarchical clus-
ter analysis of 46 such genes is summarized in Fig. 6, and those with
the most noteworthy and significant expression changes in response
to the treatments are listed in Table 1. The genes upregulated by
the LPS challenge included those coding for chemokine ligands 1, 2,
4, 5, 7, 9 (Cxcl1 = 84.30-fold, Ccl2 = 16.95-fold, Ccl4 = 9.80-fold,
Ccl5 = 38.26-fold, Cxcl5 = 33.19, Cxcl9 = 73.44-fold,) IL-1β
(Il1β = 24.70-fold), IL-6 receptor (Il6 = 7.57-fold) and nitric oxide syn-
thase (Nos2 = 369.22-fold). Only a few genes were downregulated by
the LPS challenge, including Tgfb2 (−1.73-fold), Sirpa (−2.42-fold),
Tlr5 (−3.42-fold) and Myl2 (−4.46-fold).
The levels of expression of some inflammation-related genes strongly
downregulated by aspirin are highlighted in Fig. 7. Aspirin treatment
in unchallenged cells affected fewer, but similarly impor
tant microglial genes involved in pro- and anti-inflammatory processes.
In unchallenged cells the genes downregulated by aspirin (0.1 mM
or 1 mM) included the interleukin 1 receptor antagonist
(Il1rn = −1.37-fold; −1.44-fold), the anti-inflammatory DNA damage
inducible transcript 3 (Ddit = −1.43-fold, and −1.79-fold), the pro-in-
flammatory IL6 (Il6 = −1.23-fold; −1.55-fold) and the pro-inflam-
matory chemokine (C-C motif) receptor 1(Ccr1 = −1.42-fold,
−1.44-fold). When aspirin was co-administered to LPS-challenged cul-
tures (Table 1), a more complex picture emerged. Some of the LPS-up-
regulated genes were inhibited by aspirin, as seen in the case of Ccr1
(Fig. 7A), IL1rn (Fig. 7B) or Nos2 (Fig. 7D). Kng1 (Fig. 7C), a pro-inflam-
matory gene was downregulated by both aspirin treatments following
LPS challenge. Other genes were further upregulated by aspirin when
applied to LPS-challenged microglia such as Ccl5 or Csf2, or the pro-in-
flammatory Ccl4 (Table 1).
4. Discussion
Microglial activation results in profound morphological, functional
and gene expression changes that activate both pro- and anti-inflam-
matory mechanisms (Kroner et al., 2014) that in turn not only pro-
tect the nervous tissue but can elicit chronic inflammation that could
lead to the development of neuropathological conditions (Jones and
Thomsen, 2013; Long-Smith et al., 2009). Aspirin, one of
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Fig. 6. Hierarchical cluster analysis of inflammation related genes.Pure microglial cultures (subDIV4) were maintained and treated as described in the Methods section. Cells (subDIV4)
were cultured with or without LPS for 24 h in the presence or absence of aspirin. Aspirin: 0.1 mM or 1 mM; LPS: 20 ng/ml; LPS + aspirin: LPS (20 ng/ml) + aspirin (0.1 mM or 1 mM).
For hierarchical cluster analysis and visualization, the Hierarchical Clustering Explorer (v3.0) software was used. The complete linkage clustering method was applied with Euclidean
distance metric. The heat map depicts expression values relative to control samples on a log⁠2 scale (overexpression: red, repression: green and no change: black). Missing values are
indicated in grey.
the most commonly used drugs, is noted for its strong anti-inflamma-
tory actions. It acetylates the active site of the enzyme COX, and irre-
versibly blocks the conversion of arachidonic acid to prostanoid (Vane
and Botting, 2003). Apart from its classical beneficial role in cardiovas-
cular diseases, however, aspirin may be beneficial in neuroinflamma-
tion-related disorders given that appropriate target cells, the microglia,
are present in the nervous tissue.
In the present study we investigated the complex pleiotropic, ben-
eficial effects of aspirin on the modulation of inflammation by quan
titatively analyzing numerous morphological, functional (phagocytosis,
cytokine release) and gene expression parameters in pure, secondary
microglial cultures. As our cultures were >99% pure, they provided a
unique opportunity to study these functional and expression parameters
without the significant influence of any contaminating cell types. This
is a crucial factor when, for example, the levels of secreted pro- and
anti-inflammatory peptides or gene expression levels are measured, as
other cell types in the CNS are also capable of expressing such genes
(Gruol et al., 2014).
9
UN
CO
RR
EC
TE
D
PR
OO
F
D. Kata et al. Brain Research Bulletin xxx (2017) xxx-xxx
Table 1
Differentially expressed transcripts in aspirin-treated pure microglial cells with or without LPS challenge.
Gene
Name
NCBI Reference Sequence ID
RGD ID LPS
Aspirin
0.1 mM
Aspirin
1 mM
LPS + Aspirin
0.1 mM
LPS + Aspirin
1 mM
Ccl2 Chemokine ligand 2
NM_031530.1
RGD ID 3645
+16.95 +1.14 +1.70 +20.92 +21.35
Ccl3 Chemokine ligand 3
NM_013025.2
RGD ID 3647
+ 11.33 −1.01 −1.31 +18.41 +24.79
Ccl4 Chemokine ligand 4
NM_053858.1
RGD ID 620441
+9.80 −1.05 +1.06 +17.68 +29.80
Ccl5 Chemokine ligand 5
NM_031116.3
RGD ID 69069
+38.26 +1.02 +1.35 +84.12 +62.69
Ccl7 Chemokine ligand 7
NM_001007612.1
RGD ID 1359152
+11.48 −1.14 +1.50 +10.82 +11.82
Ccr1 Chemokine receptor 1
NM_020542.2
RGD ID 708446
+4.51 −1.42 −1.44 +2.16 +1.29
Cxcl1 Chemokine ligand 1 (melanoma growth-stimulating
activity, alpha)
NM_030845.1
RGD ID 619869
+84.30 −1.51 +4.11 +43.46 +246.78
Cxcl2 Chemokine ligand 2
NM_053647.1
RGD ID 70069
+69.02 −1.37 +1.73 +63.70 +60.07
Cxcl5 Chemokine ligand 5 (Cxcl6)
NM_022214.1
RGD ID 708540
+33.19 +1.41 +2.11 +34.89 +46.37
Cxcl9 Chemokine ligand 9
NM_145672.4
RGD ID 628798
+73.44 +1.40 +1.22 +86.22 +68.51
Cxcl10 Chemokine ligand 10
NM_139089.1
RGD ID 620209
+2.83 −1.30 −1.24 +3.93 +3.21
Csf1 Colony stimulating factor-1
AF515736.1
RGD ID621063
+1.31 −1.49 −1.03 +1.48 +1.30
Csf2 Colony stimulating factor-2
XM_001074265.1(old)
NM_053852.1
RGD ID621065
+10.01 +1.20 −1.00 +20.66 +14.84
Csf3 Colony stimulating factor 3
NM_017104.1 (old), NM_017104.2
RGD ID 2426
+305.58 +1.23 +4.96 +282.90 +278.46
Ddit3 DNA-damage inducible transcript 3
NM_001109986.1
RGD ID 62391
+1.25 −1.43 −1.79 +1.14 +1.04
Il1β Interleukin 1 beta
NM_031512.2
RGD ID 2891
+24.70 +1.18 +1.62 +19.88 +22.98
Il1rap Interleukin 1 receptor accessory protein
NM_012968.1
RGD ID2893
+1.97 −1.02 +1.06 +2.30 +2.08
Il1rn Interleukin 1 receptor antagonist
NM_022194.2
RGD ID 621159
+2.83 −1.37 −1.44 +2.02 +1.64
Il6 Interleukin 6
M26744.1
RGD ID 2901
+7.57 −1.23 −1.55 +10.82 +7.22
Il10 Interleukin 10
NM_012854.2
RGD ID 2886
+8.47 +2.01 +1.04 +6.28 +11.87
Il18 IFN-gamma-inducing factor IL-18
AY077842.1
RGD ID 2889
+2.24 +1.63 −1.29 +1.90 +2.03
Kng1 Kininogen 1
NM_012696.2
RGD ID 2980
+1.04 −1.36 −1.55 −2.75 −2.82
Nos2 Nitric oxide synthase
U26686.1
RGD ID 3185
+369.22 −1.28 +1.78 +73.06 +51.21
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Table 1 (Continued)
Gene
Name
NCBI Reference Sequence ID
RGD ID LPS
Aspirin
0.1 mM
Aspirin
1 mM
LPS + Aspirin
0.1 mM
LPS + Aspirin
1 mM
Pla2g4a Phospholipase A2, group IVA (cytosolic, calcium-
dependent)
NM_133551.2
RGD ID 67366
+1.73 −1.33 −1.16 +1.66 +1.07
Ptgs2 Prostaglandin endoperoxide synthase 2
NM_017232.3
RGD ID 620349
+16.83 −1.33 +2.14 +11.76 +12.55
Sirpa The signal-regulatory protein a
NM_013016.2
RGD ID 3449
−2.42 −1.22 +1.04 −2.84 −2.63
Tgfb1 Transforming growth factor, beta 1
NM_021578.2
RGD ID 69051
−1.21 +1.05 −1.10 +1.25 +1.34
Tgfb2 Transforming growth factor, beta 2
NM_031131.1
RGD ID 70491
−1.73 −1.15 −1.43 −1.47 −2.41
Tlr2 Toll-like receptor 2
NM_198769.2
RGD ID 735138
−1.03 −1.49 −1.22 +1.63 +1.63
Tlr7 Toll-like receptor 7
EF032637.1
RGD ID 1563357
+2.71 +1.05 −1.36 +1.79 +2.21
The National Center for Biotechnology Information (NCBI) Reference Sequence Database can be retrieved at http://www.ncbi.nlm.nih.gov/refseq/. A description of a gene function (RGD
ID) can be found in The Rat Genome Database 2015 (Shimoyama et al., 2015) at http://rgd.mcw.edu/. Data are expressed as fold-change over the expression of unchallenged and untreated
(control) microglial cells. Treatments had different effects on inflammation-related genes. Most of the genes were upregulated by LPS challenge. Aspirin, either alone or in combination
with LPS, had differential effects on the expression of certain genes. For example, aspirin treatment downregulated Tgfb2, Kng1 or Ddit3, while upregulated other genes such as Csf3, IL10
and CxCl1 in unchallenged cells. In LPS-challenged microglia, aspirin inhibited IL1rn, Ccr1, Kng1, Nos2, while it had a synergistic effect with LPS on others (e.g. Cxcl5, Ccl4, Csf2).
Aspirin reversed the morphological effects of LPS-induced microglia
activation through the increase of the area, perimeter and TI values; the
combined treatment with LPS also inhibited this activation through the
development of microspikes and inducing the cells to become more ram-
ified. Aspirin also affected the protein synthesis of Iba1, a Ca⁠2+-binding
protein that is implicated in actin cytoskeleton remodeling (Ohsawa et
al., 2004; Szabo et al., 2016).
LPS is a potent activator of microglial phagocytosis (Kata et al.,
2016; Lund et al., 2006; Szabo and Gulya, 2013; Szabo et al., 2016),
a crucial factor both in normal and pathologic functions of the CNS
(Kettenmann et al., 2011). Alteration of this function could be harm-
ful (Hickman and El Khoury, 2014; Lue et al., 2015). Pro-inflamma-
tory phenotypes are associated with increased phagocytic activity, and
blocking of phagocytosis may prevent some forms of inflammatory neu-
rodegeneration; this may be beneficial under different neuropatholog-
ical conditions (He et al., 2014; Neher et al., 2011). Aspirin inhibited
phagocytosis in the LPS-challenged microglia only, while it did not in-
hibit the basal phagocytotic activity in unchallenged cells, a physiologi-
cal microglial function crucial for the healthy CNS.
LPS is the main ligad for Toll-like receptor 4 (TLR4). TLR4-in-
duced signalling activates the NF-κB and MAPK pathways leading to
the production of pro-inflammatory cytokines (Fuentes et al., 2016;
Korneev et al., 2017). Aspirin inhibits the production of pro-inflam-
matory cytokines through the suppression of LPS-induced NF-κB and
MAPK pathways in microglial cells (Cianciulli et al., 2016; Sun et al.,
2017; Yang et al., 2014). NF-κB activity is suppressed in the cyto-
plasm with an inhibitory IκB protein. The phosphorylation and degra-
dation of IκB activates NF-κB and allows to the NF-κB dimer to translo-
cate to the nucleus and activate target genes such as IL1β and TNF-α
(Sun et al., 2017; Yang et al., 2014). LPS-stimutated degradation of
IκB could be strongly inhibited by aspirin (Yang et al., 2014). Anti-in-
flammatory property is mediated by inhibition of several members
of MAPK family, e.g., p38 MAPK and ERK1/2 (Jung et al., 2009;
Li et al., 2017); according to recent data, aspirin enhances the
inhibition of p38-MAPK and ERK phosphorylation in a microglial cell
line (Yang et al., 2014).
Cytokines are important to the normal and pathologic immunomod-
ulatory functions of the microglia. Previous studies demonstrated a
strong relationship between cytokines and neurodegenerative diseases
(McGeer and McGeer, 2010; Smith et al., 2012). Microglial cells acti-
vated by β-amyloid deposits produce toxic mediators and pro-inflamma-
tory cytokines such as IL-1β, IL-6, TNF-α and iNos that could result in
chronic inflammation (Benveniste et al., 2001). High level of IL-1β could
be observed in the vicinity of amyloid plaques of AD patients (McGeer et
al., 1993) that could be responsible for plaque accumulation (Akiyama
et al., 2000). COX-2 is also increased in AD patients (Akiyama et al.,
2000). Recent attempts have been made to ameliorate neuroinflamma-
tion through the suppression of microglial activation both in vivo and in
vitro (Lim et al., 2015; Wang et al., 2011; Yang et al., 2016). Similarly
to the findings for AD, previous studies also suggested that activated mi-
croglia could be associated with neuronal loss during PD due to the acti-
vation of cytokines, COX-2 and iNos expression (Orr et al., 2002; Phani
et al., 2012) or increased levels of TNF-α and nitrogen oxide could cause
demyelination in MS (Minagar et al., 2002).
As expected, both pro- (IL-1β, TNF-α) and anti-inflammatory (IL-10)
cytokines were increased in LPS-challenged microglia as compared with
the unchallenged cells. Aspirin did not significantly affect the basal
cytokine levels in unchallenged cells, but strongly reduced the lev-
els of the pro-inflammatory cytokines IL-1β and TNF-α when tested in
LPS-challenged microglia. Besides the inhibition of these pro-inflamma-
tory agents, aspirin was also able to elevate the anti-inflammatory IL-10
in LPS-challenged cells. Thus, aspirin is remarkably beneficial as it con-
comitantly decreased pro-inflammation-related cytokines but increased
anti-inflammation-related cytokine peptides in immunochallenged cells.
We also demonstrated that aspirin, LPS and their combination had
differential effects on the expression of several inflammation-related
genes in pure microglial cells. Some of these genes encode
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Fig. 7. Relative expression levels of various inflammation-related genes identified by real-time PCR in pure microglia cells.Pure microglial cultures (subDIV4) were maintained and treated
as described in the Methods section. The transcription levels of the chemokine receptor 1 (Ccr1, A), the interleukin 1 receptor antagonist (IL1rn, B), the kininogen 1 (Kng1, C) and the
nitric oxide synthase (Nos2, D) genes are shown in unchallenged (control), LPS-challenged and LPS-challenged + aspirin-treated cells. Except for Kng1, these pro-inflammatory genes were
upregulated in LPS-challenged cells but were all strongly inhibited by both doses of aspirin. Relative expression levels (on a log⁠2 scale) ± SEM from at least 3 separate experiments are
shown for each condition. Data were analyzed with two-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001.
markers that can be related to different microglia subtypes proposed
as M1 or M2 phenotypes (Moehle and West, 2015; Orihuela et al.,
2016). In this context, for example, the pro-inflammatory IL1β, IL6,
IL18, Cxcl9, TNF-α, Cxcl10, and the chemokine Ccl5, genes encode M1
markers, while the anti-inflammatory IL10 and the pro-inflammatory
Tgfb2 genes are M2 markers (Franco and Fernández-Suárez, 2015). In an
LPS-based animal model for Parkinson’s disease, a Rho kinase inhibitor
reversed the inflammatory M1 to anti-inflammatory M2 microglia, de-
creased NF-кB activation, and inhibited IL-12 and TNF-α generation (He
et al., 2016), demonstrating a protective effect against LPS-mediated
dopaminergic degeneration. It must be noted, however, that the concept
of M1/M2 polarization of microglia cells is not universally accepted and
needs reassessment (Martinez and Gordon, 2014; Ransohoff, 2016).
Our study demonstrated that several genes were upregulated after
LPS challenge, confirming its strong pro-inflammatory effects on mi-
croglia. Aspirin, both alone and in combination with LPS, displayed dif-
ferent effects on microglial gene expression. It suppressed the pro-in-
flammatory effects of LPS on some genes such as Ccr1 and Nos2. It
may be of importance that Ccr1 was previously associated with both
MS and experimental autoimmune encephalomyelitis (Rottman et al.,
2000) and Ccr1 protein was localized around the demyelinating plaques
(Eltayeb et al., 2007). In our experiment (Fig. 7A) both aspirin doses
decreased Ccr1 expression. Multiple studies suggested
that Nos2 has a central role in inflammatory reactions and pathogenesis
of certain neurodegenerative diseases (Akiyama et al., 2000; Block and
Hong, 2005; Galea and Feinstein, 1999). Thus, downregulating Nos2 ex-
pression could be crucial for possible future therapies. We showed that
aspirin inhibited Nos2 expression significantly in LPS-challenged mi-
croglia. Kininogen (Kng1) is well known for its pro-inflammatory prop-
erties (Sharma and Yusof , 1998; Stewart et al., 1997) as it increases the
release of inflammatory cytokines and affects the formation of inflam-
matory exudate and pain (Ueno and Oh-ishi, 2003).
Aspirin also increased the expression of genes that were predomi-
nantly anti-inflammatory e.g. IL10, Tgfb1 or Ccl5. IL-10 is a well known
anti-inflammatory cytokine that limits the production of pro-inflamma-
tory cytokines including IL-1α and -β, IL-6, IL-12, IL-18, and TNF-α
(Couper et al., 2008). Previous studies showed that Tgfb1 had a pro-
tective effect against excitotoxicity and the loss of this protein resulted
in neurodegeneration (Brionne et al., 2003). Ccl5 was also upregulated
in our studies. Although Ccl5 was demonstrated to induce pro-inflam-
matory mechanisms (Skuljec et al., 2011), it was also shown to ame-
liorate AD-like pathology by recruiting microglia to β-amyloid deposits
(Lee et al., 2012) and to protect against neuronal injury (Campbell et
al., 2013; Lim and Mocchetti, 2015). Upregulation of such anti-inflam-
matory genes in neurodegenerative disorders could be beneficial.
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As activated microglia often damage neuronal tissues (Hong et al.,
2016; Lui et al., 2016) or cause chronic inflammation by excessive cy-
tokine production combined with high level of phagocytosis, effective
inhibition of pro-inflammatory actions by aspirin could be an important
prophylactic therapy in preventing neuroinflammation and thus neu-
rodegeneration. Our data indicate that aspirin beneficially regulates mi-
croglia, cells that could be targets in treating or preventing neurodegen-
erative disorders. With respect to the large population who receives as-
pirin for pain medication or prevention of a number of pathologic con-
ditions, to study the interactions of this drug with the nervous system
is even more important. Early observations revealed that NSAIDs could
reduce the risk of AD (McGeer et al., 1996; Stewart et al., 1997), a no-
tion that has not been proven in randomised controlled trials assessing
the efficacies of aspirin, steroidal and non-steroidal anti-inflammatory
drugs in AD (Jaturapatporn et al., 2012). However, we recently demon-
strated that rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor regulated microglial pro- and anti-in-
flammatory functions very favorably (Kata et al., 2016). As the effects of
aspirin on selected morphological, functional and gene expression char-
acteristics of microglia are very similar to that of rosuvastatin, and these
drugs are frequently prescribed together for a number of cardiovascu-
lar illnesses, their extended use may have contributed to the lower than
expected incidence of AD (Schrijvers et al., 2012). Thus, the individual
and combined effects of aspirin and rosuvastatin on microglial functions
should be further analyzed for a prophylactic therapeutic approach in
neurodegenerative disorders.
5. Conclusion
Aspirin elicits strong responses to microglial functions in LPS-chal-
lenged pure microglial cells. The most important pleiotropic beneficial
effects of aspirin are 1) the robust inhibition of phagocytosis in activated
microglia, 2) the inhibition of synthesis of pro-inflammatory cytokines
combined with a very strong stimulation of anti-inflammatory cytokine
production, and 3) the beneficial differential expression of a number
of inflammation-related genes. Such beneficial regulation of microglial
functions could point to the possible benefits of aspirin therapy in cer-
tain neuroinflammatory and neurodegenerative diseases.
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